Guardant Health (NASDAQ:GH) Now Covered by Analysts at Barclays

Barclays initiated coverage on shares of Guardant Health (NASDAQ:GH) in a research note published on Thursday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $60.00 price target on the stock.

Several other analysts also recently issued reports on the stock. Sanford C. Bernstein reduced their price target on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, October 30th. The Goldman Sachs Group raised their target price on Guardant Health from $32.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Leerink Partners decreased their price target on Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Thursday, October 17th. Guggenheim restated a “buy” rating on shares of Guardant Health in a research note on Wednesday. Finally, JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $48.00 to $50.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Sixteen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $41.81.

Guardant Health Stock Up 3.0 %

Shares of NASDAQ GH opened at $48.60 on Thursday. Guardant Health has a 12-month low of $15.81 and a 12-month high of $49.86. The firm has a market cap of $6.01 billion, a PE ratio of -11.46 and a beta of 1.28. The company’s fifty day simple moving average is $34.89 and its 200 day simple moving average is $29.39.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, November 6th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.33). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 1,200.44%. The firm had revenue of $191.48 million during the quarter, compared to analyst estimates of $170.49 million. During the same quarter in the prior year, the business earned ($0.73) earnings per share. The business’s quarterly revenue was up 33.9% on a year-over-year basis. On average, equities analysts predict that Guardant Health will post -3.44 earnings per share for the current year.

Insider Activity

In other news, Director Musa Tariq sold 2,320 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the transaction, the director now directly owns 2,676 shares of the company’s stock, valued at $93,660. This trade represents a 46.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Meghan V. Joyce sold 2,896 shares of the firm’s stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the transaction, the director now directly owns 7,648 shares of the company’s stock, valued at $228,675.20. The trade was a 27.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,548 shares of company stock valued at $179,782 in the last 90 days. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. R Squared Ltd bought a new stake in shares of Guardant Health during the fourth quarter valued at about $26,000. JNBA Financial Advisors purchased a new position in Guardant Health during the third quarter valued at approximately $26,000. Ashton Thomas Securities LLC bought a new stake in Guardant Health during the 3rd quarter worth approximately $34,000. Quarry LP purchased a new stake in Guardant Health in the 2nd quarter worth approximately $44,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Guardant Health in the 2nd quarter valued at $71,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.